<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04671160</url>
  </required_header>
  <id_info>
    <org_study_id>M000000346978</org_study_id>
    <nct_id>NCT04671160</nct_id>
  </id_info>
  <brief_title>Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.</brief_title>
  <official_title>Impact of Continuous Veno-venous Hemodiafiltration on Efficacy of Administration of Prophylactic Doses of Enoxaparin or Fondaparinux in Critically Ill Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose of anticoagulant prophylaxis in patients with continuous veno-venous hemodiafiltration&#xD;
      may be insufficient to keep anti-Xa factor activity in prophylactic range.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coagulation disorders are one of the most common complications in critically ill patients.&#xD;
      Among them deep vein thrombosis and pulmonary embolism are the most significant factors&#xD;
      increasing morbidity and mortality in ICU patients. Use of anticoagulant prophylaxis aims to&#xD;
      prevent these dangerous complications. Most commonly used anticoagulant prophylaxis agents&#xD;
      are low molecular weight heparins (LMWH). LMWH therapeutic efficiency is measured with&#xD;
      activity of anti-Xa factor, that should range between 0.2 and 0.4 IU/mL in order to prevent&#xD;
      thrombotic complications. Due to grave general condition, critically ill patients may often&#xD;
      develop acute kidney injury (AKI), that requires renal replacement therapy (RRT). Because of&#xD;
      haemodynamic instability the safest therapeutic choice seems to be continuous veno-venous&#xD;
      hemodiafiltration (CVVHDF). This RRT mode removes particles in the size of few daltons even&#xD;
      up to 10 kilodaltons (kDa) such as metabolic product waste, ions, hormones etc. LMWH with&#xD;
      average molecular weight of 4.5 kDa and fondaparinux with average molecular weight of 1.7 kDa&#xD;
      may be removed during CVVHDF resulting in insufficient activity of anti-Xa factor thus&#xD;
      increasing the risk of thrombotic complications in critically ill patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 4, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Anti-Xa assay</measure>
    <time_frame>9 hours</time_frame>
    <description>Anti-Xa assay as a tool to measure anticoagulation activity in subjects just before administration of anticoagulant prophylaxis, 3 hours, 6 hours and 9 hours after administration of prophylactic dose of enoxaparin 40 mg sc. once daily or fondaparinux 2.5 mg sc. once daily.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Assessment of Activity of Anti-Xa Factor in Patients Treated With Continuous Veno-venous Hemodiafiltration Receiving Anticoagulant Prophylaxis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Group treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Group treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Group not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Group not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Assessment the activity of anti-Xa factor.</intervention_name>
    <description>Assessment the activity of anti-Xa factor in patients treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis, patients treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis, patients not treated with CVVHDF and receiving enoxaparin as anticoagulant prophylaxis and patients not treated with CVVHDF and receiving fondaparinux as anticoagulant prophylaxis.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All male and female Intensive Care Unit adult patients (18 - 80 y.o.) requiring continuous&#xD;
        veno-venous hemodiafiltration (CVVHDF) and receiving prophylactic doses of enoxaparin or&#xD;
        fondaparinux.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All adult Intensive Care Unit patients between 18 and 80 years old requiring treatment&#xD;
             with CVVHDF;&#xD;
&#xD;
          -  Indications for anticoagulant prophylaxis with enoxaparin 40 mg sc. once daily or&#xD;
             fondaparinux 2.5 mg sc. once daily;&#xD;
&#xD;
          -  Treatment with continuous veno-venous hemodiafiltration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Indications for low molecular weight heparin use other than anticoagulant prophylaxis;&#xD;
&#xD;
          -  Intracranial hemorrhage;&#xD;
&#xD;
          -  Incident of serious bleeding within a week before admission to ICU, if not managed;&#xD;
&#xD;
          -  Disseminated intravascular coagulopathy;&#xD;
&#xD;
          -  Heparin induced thrombocytopenia;&#xD;
&#xD;
          -  Hypersensitivity or allergic reaction to enoxaparin or fondaparinux;&#xD;
&#xD;
          -  Thrombocytopenia &lt; 50 G/L;&#xD;
&#xD;
          -  Prothrombin time &lt; 20% or INR (international normalized ratio) &gt; 1.7;&#xD;
&#xD;
          -  Use of antiplatelet drugs;&#xD;
&#xD;
          -  Presence of congenital coagulopathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aleksander Aszkielowicz, M.D.</last_name>
    <phone>509465855</phone>
    <phone_ext>0048</phone_ext>
    <email>aszkielowicz@gumed.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Radoslaw Owczuk, Prof.</last_name>
    <phone>605408140</phone>
    <phone_ext>0048</phone_ext>
    <email>r.owczuk@gumed.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Gdansk - Departament of Anesthesiology and Intensive Care</name>
      <address>
        <city>Gda≈Ñsk</city>
        <state>Pomorskie</state>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <last_name>Radoslaw Owczuk, Prof.</last_name>
      <phone>583493270</phone>
      <phone_ext>0048</phone_ext>
      <email>klanest@gumed.edu.pl</email>
    </contact>
    <contact_backup>
      <last_name>Aleksander Aszkielowicz, M.D.</last_name>
      <phone>509465855</phone>
      <phone_ext>0048</phone_ext>
      <email>aszkielowicz@gumed.edu.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Radoslaw Owczuk, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksander Aszkielowicz, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alicja Filipczyk, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>continuous veno-venous hemodiafiltration</keyword>
  <keyword>enoxaparin</keyword>
  <keyword>low molecular weight heparin</keyword>
  <keyword>LMWH</keyword>
  <keyword>CVVHDF</keyword>
  <keyword>anticoagulant prophylaxis</keyword>
  <keyword>critically ill</keyword>
  <keyword>fondaparinux</keyword>
  <keyword>anti-Xa activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

